anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A receptor of dopamine is provided to improve selectivity and binding properties to dopamine in neutral pH buffer solution, so that it is useful for detecting dopamine in aqueous solution and blood or promoting activity of dopamine in blood. A receptor of dopamine represented by the formula(1) is provided, wherein R is methyl or ethyl, and R' is O(CH2)4SO3^-Na^+. A nitrogen atom of phenyl oxazoline substituent of the dopamine receptor forms a hydrogen bonding with an ammonium ion of dopamine; a benzene ring of the dopamine receptor forms the cation-pi interaction with an ammonium ion of dopamine. An ether bonding or an oxygen atom of a butanesulfonate group of the dopamine receptor forms a hydrogen bonding with a catechol hydroxy group of dopamine. A phenyl group of the dopamine receptor forms the pi-pi interaction with a benzene ring of dopamine. A method for producing the dopamine receptor comprises the steps of: (a) reacting aminoalcohol represented by the formula(2) with triacid represented by the formula(3) to prepare compounds represented by the formula(4); (b) substituting OR' of compounds represented by the formula(4) by OH of a base to prepare compounds by the formula(5); and (c) reacting the compounds represented by the formula(5) with 1,4-butanesultone under basic conditions. In the formulae(2)-(5), R is methyl or ethyl and R' is TBS(tert-butyldimethylsilyl).
Patients having undergone adenotonsillectomy at Texas Children's Hospital admitted for overnight observation based on our institutional protocol will be enrolled. A Wrist OX 3150 (Nonin Medical) will be placed in PACU with saturations recorded until the following morning after the surgery. The patient will undergo pulse oximetry monitoring separately based on the hospital protocol that will be used to guide care. Data from the Wrist Ox will not be avail to the treatment team and will only be analyzed for research purposes.
The present invention relates to an antioxidative composition containing an Acer pictum var. mono (Maxim.) Maxim. ex Franch leaf extract as an active ingredient, and a production method thereof. The Acer pictum var. mono (Maxim.) Maxim. ex Franch leaf extract of the present invention removes active oxygen species (DPPH, ABTS radical) directly, has reducing power, and also removes active oxygen. In addition, the Acer pictum var. mono (Maxim.) Maxim. ex Franch leaf extract is able to suppress DNA damage due to oxidative stress and also contains antioxidant components (polyphenol, flavonoid), thereby being useful as an antioxidant composition.
Patients will undergo endoscopic nasobiliary drainage (ENBD) when bile duct stones were removed clearly with ERCP. The nose bile duct will be pulled out 3-5 days later if no cholangitis occurrence.
Series of 6 standard of care nutrition visits delivered by clinic dieticians. These are a mix of individual and group sessions.
PURPOSE:To provide a powdery bathing agent composed of a main agent consisting of a water-soluble inorganic salt powder and a mixture of a water-soluble organic acid powder and an inorganic carbonate powder and capable of diffusing the main agent throughout the whole bath water without stirring simply by throwing the agent into the bathtub in bathing. CONSTITUTION:The objective bathing agent contains (A) a main agent consisting of a water-soluble inorganic salt powder (e.g. sodium chloride, etc., effective in preventing the chill after bath, sodium borate to improve the cleaning effect, etc.) and (B) a mixture of a water-soluble organic acid powder (e.g. malic acid, citric acid, etc.) and a water-soluble inorganic carbonate powder capable of generating carbon dioxide gas by the reaction with said organic acid (e.g. sodium carbonate, sodium bicarbonate, etc.). When the bathing agent is thrown into bath water in a bathtub, the organic acid powder and the inorganic carbonate powder are rapidly dissolved in water near the surface of the bath water and the main agent is forcibly diffused by the bubble of carbon dioxide gas generated by the reaction of the above powdery components.
Carcinogenesis

Citalopram was administered in the diet to NMRI/BOM strain mice and COBS WI strain rats for 18 and 24 months, respectively. There was no evidence for carcinogenicity of citalopram in mice receiving up to 240 mg/kg/day, which is equivalent to 20 times the maximum recommended human daily dose (MRHD) of 60 mg on a surface area (mg/m2) basis. There was an increased incidence of small intestine carcinoma in rats receiving 8 or 24 mg/kg/day, doses which are approximately 1.3 and 4 times the MRHD, respectively, on a mg/m2 basis. A no-effect dose for this finding was not established. The relevance of these findings to humans is unknown.

Mutagenesis

Citalopram was mutagenic in the in vitro bacterial reverse muta¬tion assay (Ames test) in 2 of 5 bacterial strains (Salmonella TA98 and TA1537) in the absence of metabolic activation. It was clas¬togenic in the in vitro Chinese hamster lung cell assay for chro¬mosomal aberrations in the presence and absence of metabolic activation. Citalopram was not mutagenic in the in vitro mam¬malian forward gene mutation assay (HPRT) in mouse lymphoma cells or in a coupled in vitro/in vivo unscheduled DNA synthesis (UDS) assay in rat liver. It was not clastogenic in the in vitro chro¬mosomal aberration assay in human lymphocytes or in two in vivo mouse micronucleus assays.

Impairment of Fertility

When citalopram was administered orally to 16 male and 24 female rats prior to and throughout mating and gestation at doses of 32, 48, and 72 mg/kg/day, mating was decreased at all doses, and fertility was decreased at doses ≥ 32 mg/kg/day, approxi¬mately 5 times the MRHD of 60 mg/day on a body surface area (mg/m2) basis. Gestation duration was increased at 48 mg/kg/day, approximately 8 times the MRHD.
A procedure for the preparation of cicloalca/4,5/pirrolo/2,3-g/isoquinolinas. Is to reactively replace a general compound (I) in the atom of isoquinolic nitrogen. Compound (II) is obtained which optionally is subject to the following operations: a) isomerize the mixture to a final relationship that promptly comprises the isomero trans. B) separate the isomero trans of the mixture obtained. C) resolve the racemical mixture obtained in the optical antipodas. D) convert the obtained compound or a non pharmaceutically acceptable addition salt in a salt that is. R is rent, hydroxyalkyl, aryl hydroxyalkyl, alcoxyalkyl, aciloxyalkyl, acilalkyl, alkenyl and others; x is oxygen or sulfur; n es 3, 4, 5 or 6. (Machine-translation by Google Translate, not legally binding)
PURPOSE:To purify the titled compound useful as an antitumor agent, etc. industrially advantageously, by treating an aqueous solution containing interleukin 2 with combined three or more carriers of porous glass bead chromatography carrier, cation exchange chromatography carrier, gel filtration chromatography carrier, etc. CONSTITUTION:An aqueous solution of interleukin 2(IL-2 for short) is purified with combined three or more carriers of (A) porous glass bead chromatography carrier, (B) cation exchange chromatography carrier, (C) gel filtration chromato- graphy carrier, (D) hydrophobic chromatography carrier, and (E) metal chelate chromatography carrier and concentrated. The order of the combination of these chromatography carriers is chosen arbitrarily, and the same carrier may be used two or more times. The combination of three or more carriers can carry out a large amount of treatment relatively simply, and provide IL-2 in high yield in high purity. IL-2 is expected to be useful as a remedy for immune incompetence or autoimmune disease, etc.
1. Objectives(s): We plan to conduct a feasibility pilot trial of the Family Partnership Intervention (FPI) compared to patients in the HF Wait-list (WL) condition. We plan to demonstrate feasibility, estimate variances of major outcome variables, and to obtain preliminary estimates of effect sizes in preparation for subsequent grant applications. We will be able to develop a cost-effectiveness model for the relative benefit of FPI vs. no family-based for use in longer-term studies.
2. Research Design: This is a short-term, randomized clinical trial which will involve assessments for participants in the FPI condition at a pre-intervention Baseline point, immediately post-intervention, and 6 months post-intervention. Participants in the WL condition will be assessed at Baseline, undergo an approximately 8 week waiting period, and then the FPI. A longer follow-up is not planned based on the purpose of this study as a feasibility trial.
3. Methodology: We plan to randomize 40 Veterans and their family members to either the FPI condition or WL condition, in equal proportions. We will recruit patients with at least Stage C Heart Failure (NYHA class I - IV) from the Cardiology clinic of the Philadelphia VAMC. FPI will involve 4-6 hours of intervention delivered over a period of 6-8 weeks. Assessments at a pre-treatment baseline point, 8 weeks (immediately post-treatment), and 6 months will cover the following domains: a) patients' demographic characteristics and clinical functioning, b) self-care, including self-management of symptoms, knowledge of HF, and adherence to medication and dietary intake of sodium, c) measures of family functioning relevant to the medical care of the patient, and d) health care utilization costs. Primary outcome measures will be patients' self-reported HF self-care and health care utilization costs. We anticipate that patients in the FPI condition will exhibit better self-care over time compared to patients in the WL condition. We also anticipate that patients and family members will exhibit an improved family environment and better HF knowledge.
UNLABELLED: Medullary infarction is a severe and infrequent pathology, which represents 1% of all ischemic strokes, and is also a rare complication of different surgical procedures. It is caused by the acute interruption of the blood flow of the spinal cord, manifesting itself with clinical neurological deficits related to the affected vascular territory.
METHODS: We present the case of an 80-year-old patient, with cardiovascular risk factors, who is present on post-surgical day 13, after placement of a vascular endoprosthesis for a thoracoabdominal aneurysm, sudden appearance of paraparesis with progression to paraplegia and hypoesthesia in both lower extremities. CT angiography of the aorta rules out local complications in the endoprosthesis. Medullary MRI showed images compatible with acute dorsal medullary infarction from level D9.
RESULTS: On discharge, the patient presented paraplegia and hypoesthesia of both lower extremities with fecal and urinary incontinence.
CONCLUSION: Spinal cord infarction may be limited to a vascular territory or be more extensive according to its pathogenesis. The affectation of the anterior spinal artery is the most common and is characterized by bilateral motor deficits and loss of thermoalgesic sensitivity, which could have a great impact on the quality of life of patients. Its etiology is varied, including aortic surgery within its causes. MRI is very useful for its diagnosis and currently there are no clinical guides for the optimal treatment.
Objective: Behavioral variant frontotemporal dementia (bvFTD) is a neurodegenerative condition characterized by progressive changes in behavior, cognition, and day-to-day functioning. Progression of the disease usually leads to death 3-5 years after diagnosis. However, there are reports of individuals who are initially diagnosed with bvFTD but fail to progress. These individuals are thought to have what is becoming known as phenocopy bvFTD (phFTD). Methods: This manuscript reviews a single case study of a 68-year-old male Veteran who was diagnosed with bvFTD in 2010, which has not progressed over time. Results: Review of serial neuropsychological evaluations was broadly normal with mild evidence of executive dysfunction with minimal reliable change in his performances from 2015, 2017, and 2022 evaluations. He also has not developed neuroimaging evidence of FTD. Conclusions: This case illustrates the importance of monitoring individuals over time and incorporating neuroimaging data into the diagnosis. We believe this Veteran's presentation is most consistent with what has been described as phFTD.
The invention discloses a virulent strain and a low virulent strain of porcine reproductive and respiratory syndrome similar to NADC30 and application thereof. The invention relates to a kind of NADC30 porcine reproductive and respiratory syndrome virus virulent strain, which is named as a kind of NADC30 porcine reproductive and respiratory syndrome virus SD strain, and the microorganism preservation number is as follows: CGMCC NO. 19691. By carrying out attenuated culture on the SD strain, the invention also obtains a similar NADC30 porcine reproductive and respiratory syndrome virus attenuated strain named as a similar NADC30 porcine reproductive and respiratory syndrome virus SD-R strain, and the microbial preservation number is as follows: CGMCC NO. 19692. Experiments prove that the SD strain has the characteristics of strong toxicity and stable pathogenicity to piglets, and can be used for detecting and preventing or treating similar NADC30 porcine reproductive and respiratory syndrome; the attenuated vaccine strain SD-R strain has the characteristics of high safety and good protection effect, and can be used for preventing the like NADC30 porcine reproductive and respiratory syndrome. Therefore, the SD strain and the attenuated vaccine SD-R strain thereof can be used for preparing single vaccine or combined vaccine (live or inactivated vaccine) for preventing and treating the analogous NADC30 porcine reproductive and respiratory syndrome and the like, and can also be prepared into diagnostic reagent for diagnosing the analogous NADC30 porcine reproductive and respiratory syndrome.
PURPOSE: An ester compound of 3,4,5-trimethoxyphenylacetic acid, 3,4,5-trimethoxycinnamic acid or 3,4,5-trimethoxyhydrocinnamic acid, their preparation method and a whitening cosmetics composition containing the compound are provided, which ester compound inhibits the generation of melanin and shows no toxicity or irritation to the skin. CONSTITUTION: The ester compound is represented by the formula, wherein R1 is -CH2-, -CH=CH- or -CH2-CH2-; and R2 is a thymyl group or a carvacryl group. The ester compound is prepared by dehydrating a starting material (3,4,5-trimethoxyphenylacetic acid, 3,4,5-trimethoxycinnamic acid or 3,4,5-trimethoxyhydrocinnamic acid) with thymol or carvacrol in the presence of an acid. Also the ester compound is prepared by halogenating the starting material; and reacting the halogenated compound with thymol or carvacrol in the presence of a base. Also the ester compound is prepared by converting the starting material into an acid anhydride form; and reacting the obtained acid anhydride with thymol or carvacrol. Also the ester compound is prepared by reacting the starting material with 1,3-dicyclohexylcarbodimide to obtain an active ester; and reacting the active ester with thymol or carvacrol in the presence of a base.
Anterior cutaneous nerve entrapment syndrome (ACNES) is a cause of moderate to severe chronic pain, hyperesthesia/hypoesthesia, and altered perception of heat/cold in a specific region of the anterior abdominal wall, referable to the territory of innervation of one or more anterior branches of the intercostal nerves. None of the therapeutic options currently available has proved to be effective in the long term or decisive. In recent years, we have begun to treat purely sensory neuropathies, such as this, with the implantation of wireless peripheral nerve stimulators (PNS), achieving the safety of modular and personalized analgesia. We report the case of a 41-year-old man suffering from ACNES of the 8th intercostal nerve for two years. We first performed two consecutive ultrasound-guided diagnostic blocks of the anterior cutaneous branch of the 8th intercostal right nerve and then elected the patient for ultrasound-guided nerve decompression followed by neuromodulation and pulsed-radiofrequency (PRF). Taking into account full employment, young age, and the likelihood of having to repeat the treatment several times, we considered him for Peripheral Nerve Stimulation (PNS) implantation under ultrasound guidance, and we implanted the wireless lead at the anterior branch of the right 8th intercostal nerve, and programmed tonic stimulation 100 Hz PW 200 ms. The patient reported immediate pain relief and never took medication for this problem again, at two years follow-up. PNS has had an increasing role in the management of chronic neuropathic pain, especially in merely sensitive neuropathies like ACNES. We support future research on this theme.
Remodulin initiated as a continuous IV infusion at a dose of 2.5 ng/kg/min after subjects have been assessed as hemodynamically stable in the ICU. Dose may be escalated in 1.25- to 2.5-ng/kg/min increments, up to 7.5 ng/kg/min, with a target dose of 5 ng/kg/min, based on tolerability. The dose will be maintained at the maximum tolerated dose, not to exceed 7.5 ng/kg/min for 5 days after the transplantation surgery.
PURPOSE:To stick a poultice over a long time without imparting a feeling of physical disorder, by combining two sets of specific polymers and softening agents different from each other as main components. CONSTITUTION:A polymer A soluble in both of alcohol and water, a water- retentive softening agent A compatible with said polymer A and soluble in alcohol, a polymer B soluble in alcohol but substantially insoluble in water and a softening agent B compatible with said polymer B and soluble in alcohol but substantially insoluble in water are contained as main components. For example, as the polymer A, a copolymer based on polyacrylic acid and acrylic acid is designated and, as the softening agent A, there are glycerine, acetylethanolamine or the like. For example, as the polymer B, there is a copolymer of alkyl (meth)acrylate and/or vinyl acetate and a vinyl monomer having a hydrophylic group. As the softening agent B, there are triethyl citrate, phosphoric triester or the like. This poultice is easily to the surface of the mucous membrane of the oral cavity and imparts no feeling of physical disorder even in use over a long time.
NY-ESO-1 T cells are T cells engineered to target the tumour antigen NY-ESO-1. Autologous T cells are obtained from eligible patients who have NY-ESO-1 positive tumours and who are Human Leukocyte Antigen serotype "A" serotype group (HLA2) positive. The T cells undergo lentiviral transduction with NY-ESO-1 specific nucleic acid under Good Manufacturing Practice (GMP) conditions. The patient will then undergo preconditioning chemotherapy with a regime of cyclophosphamide 60mg/kg/day day -7 and -6 followed by fludarabine 25mg/m2 day -5 to -1. They will receive autologous NY-ESO-1 T cells on day 0 and following on from that they will receive up to 14 doses of intravenous IL-2 at a dose of 100000 units per kg..
Patients receive dasatinib PO QD for 15 years in the absence of disease progression or unacceptable toxicity. After 3 months of dasatinib treatment, patients also receive venetoclax PO QD on days 1-14 of each month for 3 years in the absence of disease progression or unacceptable toxicity (patients enrolled prior to 4/1/2018 receive only dasatinib).
The present invention utilizes an extracting reagent to achieve quantitative detection of hydrophobic analytes from a biological test sample. The hydrophobic analytes can include steroids, hydrophobic peptides, and drugs. The biological test sample can include serum, plasma, whole blood, urine and spinal fluid. The hydrophobic analyte is preferably the drug cyclosporine, which is used primarily as an immunosuppressant. The biological test sample is preferably whole blood. The extracting reagent comprises a zwitterionic detergent and saponin, and optionally, a viscosity additive such as sucrose or glycerin. The detection and analysis of the hydrophobic analyte is preferably performed in an automated immunoanalyzer.
Nulliparous pregnant women and their spouses who apply to the obstetrics and gynecology clinic and outpatient clinic of the hospital where the research will be conducted will be assessed for eligibility according to the inclusion criteria, and informed consent will be obtained. Subsequently, prospective fathers will be given a Personal Information Form and the Fathers' Fear of Childbirth Scale; prospective mothers will be given a Personal Information Form, the Wijma Delivery Expectancy/Experience Questionnaire Version A, the Childbirth Self-Efficacy Inventory Short Form, and the Perception of Spousal Support in Pregnancy Scale as pre-tests. Couples will be allocated to the experimental or control group according to a block randomization list. Couples assigned to the experimental group will be included in a three-week program, attending a self-efficacy theory-based childbirth preparation program in groups of 4-5 couples, scheduled according to their availability. At the end of the sessions, brochures reflecting the educational content will be given to the couples to read at home. These couples will also receive routine care provided at the hospital, which includes standard antenatal follow-up and information about pregnancy and childbirth during physician visits. After the completion of the training, couples will receive weekly phone calls until their estimated due date to reinforce the educational content. After completing the training, the Fathers' Fear of Childbirth Scale, the Childbirth Self-Efficacy Inventory Short Form, and the Perception of Spousal Support in Pregnancy Scale will be administered again. Following childbirth, the Wijma Delivery Expectancy/Experience Questionnaire Version B will be completed by the mothers, and the birth process information form will be filled out by the researcher. Couples in the control group will undergo the same pre-test and post-test assessments as the experimental group. However, no additional intervention will be provided to these couples, and they will receive the same routine care as the experimental group.
Genetically modified non-human animals are provided that exhibit a functional lack of one or more lncRNAs. Methods and compositions for disrupting, deleting, and/or replacing lncRNA-encoding sequences are provided. Genetically modified mice that age prematurely are provided. Also provided are cells, tissues and embryos that are genetically modified to comprise a loss-of-function of one or more lncRNAs. Genetically modified non-human animals are provided that exhibit a functional lack of one or more lncRNAs. Methods and compositions for disrupting, deleting, and/or replacing lncRNA-encoding sequences are provided. Genetically modified mice that age prematurely are provided. Also provided are cells, tissues and embryos that are genetically modified to comprise a loss-of-function of one or more lncRNAs. The present invention provides compositions and methods for the diagnosis of colorectal cancer in a subject. In one embodiment, the method includes detecting methylation status of one or more genes in a sample to diagnosis the subject. The invention further relates to DNA methylation as a predictor of disease recurrence and patient prognosis, specifically in the field of cancer biology.
Group B1 (n=5) will receive the optimal PfSPZ Challenge immunizing dose from the dose-escalation phase (Stage A; 51,200 PfSPZ Challenge (NF54)), using the same standard chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), but for five instead of ten weeks. Group B1 will receive 3 injections of 51,200 PfSPZ Challenge (NF54) on days 0, 14 and 28. All volunteers in Group B1 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.